Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Felix Olash

Internal Medicine Louisville, KY Medical Doctor

NPI 1053428714 CMS profile 274268

3900 Kresge Way, Ste. 50, Louisville, KY 40207

Open in the dashboard

General payments

$9,974

645 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Felix Olash of Louisville, KY is reported in the CMS Open Payments database as having received $9,974 across 645 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,081 65
2024 General $1,057 68
2023 General $1,651 97
2022 General $1,869 127
2021 General $2,063 136
2020 General $1,256 86
2019 General $997 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Felix Olash
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Felix Olash were reported at $1,081. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Felix Olash Internal Medicine median Middle half National median
2019 $997 $159 $48–$570 $163
2020 $1,256 $119 $33–$402 $114
2021 $2,063 $135 $37–$521 $132
2022 $1,869 $141 $42–$496 $149
2023 $1,651 $149 $45–$519 $160
2024 $1,057 $154 $47–$537 $164
2025 $1,081 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,744 122 payments
  2. AbbVie, Inc. $925 52 payments
  3. Novo Nordisk Inc $772 53 payments
  4. Novartis Pharmaceuticals Corporation $666 42 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $550 41 payments
  6. Esperion Therapeutics, Inc. $462 27 payments
  7. AstraZeneca Pharmaceuticals LP $461 26 payments
  8. Pfizer Inc. $461 35 payments
  9. GlaxoSmithKline, LLC. $432 30 payments
  10. Janssen Pharmaceuticals, Inc $408 25 payments
  11. Other $3,094 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,946 642 payments
  2. Education $28 3 payments
Products named General payments · program years 2019–2025
  1. Repatha $759 57 payments
  2. EVENITY $619 41 payments
  3. Otezla $615 43 payments
  4. Prolia $523 35 payments
  5. CYCLOSET $490 37 payments
  6. AIMOVIG $480 34 payments
  7. NEXLETOL $462 27 payments
  8. Ozempic $457 31 payments
  9. GEMTESA $420 24 payments
  10. UBRELVY $406 22 payments
  11. Other $8,079 524 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

5,753

Median for Internal Medicine: 777

Drug cost

$806,836

Median for Internal Medicine: $73,373

Branded share of claims

25%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 249 $202,439
Rybelsus Semaglutide Brand 30 $46,282
Vascepa Icosapent Ethyl Brand 65 $44,038
Ozempic Semaglutide Brand 41 $43,645
Entresto Sacubitril/Valsartan Brand 44 $41,071
Tradjenta Linagliptin Brand 52 $40,920
Xarelto Rivaroxaban Brand 24 $30,218
Farxiga Dapagliflozin Propanediol Brand 21 $30,162
Praluent Pen Alirocumab Brand 46 $28,383
Jardiance Empagliflozin Brand 35 $23,639

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$120,458

Of which drugs: $54,615

Medicare patients

193

Average age 78

Services billed

4,690

100 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Ischemic heart disease 27%
Atrial fibrillation 25%
Diabetes 16%
Chronic kidney disease 16%
Depression 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,502 $30,871
Vaccine for influenza for injection into muscle 90662 Office 67 67 $5,472

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$172 — —
CYCLOSET
$130 16 —
GEMTESA
$85 26 —
Repatha
$81 52 —
Tymlos
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record